- Home
- GLBZ vs LYRA Comparison
GLBZ vs LYRA Comparison
Compare GLBZ & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLBZ
- LYRA
- Stock Information
- Founded
- GLBZ 1949
- LYRA 2005
- Country
- GLBZ United States
- LYRA United States
- Employees
- GLBZ N/A
- LYRA N/A
- Industry
- GLBZ Major Banks
- LYRA Medical/Dental Instruments
- Sector
- GLBZ Finance
- LYRA Health Care
- Exchange
- GLBZ Nasdaq
- LYRA Nasdaq
- Market Cap
- GLBZ 14.1M
- LYRA 15.0M
- IPO Year
- GLBZ N/A
- LYRA 2020
- Fundamental
- Price
- GLBZ $4.82
- LYRA $9.40
- Analyst Decision
- GLBZ
- LYRA Buy
- Analyst Count
- GLBZ 0
- LYRA 2
- Target Price
- GLBZ N/A
- LYRA $16.00
- AVG Volume (30 Days)
- GLBZ 10.3K
- LYRA 1.9M
- Earning Date
- GLBZ 07-25-2025
- LYRA 08-13-2025
- Dividend Yield
- GLBZ 2.10%
- LYRA N/A
- EPS Growth
- GLBZ N/A
- LYRA N/A
- EPS
- GLBZ 0.01
- LYRA N/A
- Revenue
- GLBZ $11,536,000.00
- LYRA $1,185,000.00
- Revenue This Year
- GLBZ N/A
- LYRA N/A
- Revenue Next Year
- GLBZ N/A
- LYRA $1,286.17
- P/E Ratio
- GLBZ $370.98
- LYRA N/A
- Revenue Growth
- GLBZ N/A
- LYRA N/A
- 52 Week Low
- GLBZ $3.86
- LYRA $3.81
- 52 Week High
- GLBZ $6.99
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- GLBZ 50.81
- LYRA 45.31
- Support Level
- GLBZ $4.02
- LYRA $10.15
- Resistance Level
- GLBZ $5.25
- LYRA $14.88
- Average True Range (ATR)
- GLBZ 0.29
- LYRA 2.03
- MACD
- GLBZ 0.01
- LYRA -0.67
- Stochastic Oscillator
- GLBZ 68.29
- LYRA 0.42
About GLBZ Glen Burnie Bancorp
Glen Burnie Bancorp is a bank holding company for The Bank of Glen Burnie. It offers retail and commercial banking services such as checking, savings, loans, mobile banking, online banking, wire transfer, ACH services, debit cards, automated teller machines, and safe deposit boxes among others. The bank generates its revenue in the form of interest income. All of the revenues are earned within the United States.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.